Contribute Try STAT+ Today

Federal prosecutors indicted Teva Pharmaceuticals (TEVA) of conspiring with other manufacturers of fixing prices for generic drugs, the seventh drug maker to be accused as part of a long-running government probe.

The Department of Justice alleged the company, which is one of the world’s largest purveyors of copycat medicines, participated in three conspiracies from at least as early as May 2013 until at least in or around Dec. 2015. The drug maker allegedly coordinated with several other companies to set prices for medicines to treat high cholesterol, arthritis, seizures, pain, skin conditions, blood clots. brain cancer, cystic fibrosis, arthritis, and hypertension.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy